HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ASBP

Aspire Biopharma Holdings, Inc.

Healthcare — Biotechnology

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

None
$8.12
$-0.23 (-2.75%)

Price History

52-Week Range
Sign in to add ASBP to a watchlist or set price alerts.

Fundamentals

Market Cap$6.92M
P/E Ratio (TTM)-
Forward P/E-
EPS (TTM)$-7.09
Dividend Yield-
Profit Margin-
Revenue Growth-
ROE-
Debt/Equity38.76
Recommendation None
Analyst Target-
Analysts-
Next Earnings -
Indexes -

Technical Indicators

RSI (14)44.4
Beta0.16
SMA 20-
SMA 40-
52-Week High$35.00
52-Week Low$0.11
50-Day Avg$4.04
200-Day Avg$5.38
Avg Volume$13.35M
Volume286.1K

Performance Analysis

NEUTRAL

ASBP presents a mixed picture with both positive and negative indicators.

~ Trading at 23% of its 52-week range.
~ RSI at 44.4 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jun 30, 2026 21:07 UTC

Back to Screener Export Report